Biogen Eyes Midyear BIIB080 Results and 2026 LITIFILIMAB Readouts
Biogen expects midyear data from its BIIB080 tau-targeting antisense oligonucleotide proof-of-concept study. Phase 3 LITIFILIMAB readouts in systemic lupus are due this year, while global approvals for high-dose Spinraza drive patient uptake and LEQEMBI adoption grows through new blood-based biomarkers support.
1. BIIB080 Tau-Targeting Program
The BIIB080 antisense oligonucleotide targeting tau showed encouraging tau reduction in Phase 1b, prompting a proof-of-concept study with multiple dosing regimens to assess cognitive benefits, with midyear data expected to guide further development.
2. Spinraza Approval and Patient Uptake
Biogen’s high-dose Spinraza has secured approvals in the US, Japan and Europe, receiving positive clinician feedback and driving strong patient uptake across major markets.
3. LITIFILIMAB Phase 3 SLE Trials
Two Phase 3 LITIFILIMAB trials in systemic lupus erythematosus are slated to read out this year, and Biogen will evaluate the totality of data—considering filings if one trial is positive and the other shows favorable trends.
4. LEQEMBI Adoption via Blood Biomarkers
Adoption of LEQEMBI maintenance therapy is accelerating as CMS permits blood-based biomarkers for confirmation, and ongoing pilot programs are encouraging physicians to consider switching patients from Kisunla to LEQEMBI.